Testimony before FDA Arthritis Advisory Committee on Anti-Nerve Growth Factor Agents being Developed for Treatment of Chronic Pain
We strongly urge the Food and Drug Administration (FDA) to permanently suspend the clinical development of these anti-nerve growth factor (anti-NGF) agents for the treatment of pain because of the dramatic safety signal seen in clinical studies of these agents demonstrating an unusually high incidence of rapid joint destruction.
See Public Citizen’s other work on the anti-nerve growth factor drug tanezumab.